Tempest: amezalpat 6-month OS improvement in HCC (21 vs 15 months); files $205M equity facility

Tempest Therapeutics, Inc.

Median OS 21 months for amezalpat arm vs 15 months control, a six-month advantage.
Hazard ratio of 0.65 for OS, stable from 0.59 at primary analysis 10 months earlier.
20/40 amezalpat patients remain in survival follow-up vs 9/30 control.
Entered new Open Market Sale Agreement to sell up to $205M of common stock.
Tempest retains all product rights; data supports potential pivotal Phase 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.